Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers

PHASE3CompletedINTERVENTIONAL
Enrollment

1,183

Participants

Timeline

Start Date

November 7, 2016

Primary Completion Date

July 19, 2018

Study Completion Date

July 19, 2018

Conditions
Meningitis, Meningococcal
Interventions
BIOLOGICAL

MenACYW conjugate vaccine

Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; 0.5 milliliter (mL), Intramuscular

BIOLOGICAL

MMR

Measles, Mumps, and Rubella Virus Vaccine Live; 0.5 mL, Subcutaneous

BIOLOGICAL

Varicella

Varicella Virus Vaccine Live; 0.5 mL, Subcutaneous

BIOLOGICAL

DTaP-IPV-HB-Hib

Diphtheria, Tetanus, Pertussis (acellular component), Hepatitis B, Poliomyelitis (inactivated), and Haemophilus influenzae type-b conjugate vaccine (adsorbed); 0.5 mL, Intramuscular

BIOLOGICAL

PCV13

Pneumococcal 13-valent Conjugate Vaccine; 0.5 mL, Intramuscular

Trial Locations (37)

162

Wŏnju

10330

Pathum Wan

10400

Rajthevi

10444

Ilsan

39670

Acapulco

41931

Daegu

61469

Gwangju

62770

Tlaltizapán

63241

Jeju City

119296

Moscow

183031

Murmansk

191025

Saint Petersburg

197022

Saint Petersburg

197101

Saint Petersburg

214014

Smolensk

350015

Krasnodar

420012

Kazan'

443079

Samara

614066

Perm

620028

Yekaterinburg

630102

Novosibirsk

634050

Tomsk

656054

Barnaul

04530

Mexico City

425-707

Ansan

431-070

Anyang

Unknown

Daejeon

400-700

Incheon

02053

Seoul

05278

Seoul

100-380

Seoul

130-702

Seoul

132-703

Seoul

139-709

Seoul

158-710

Seoul

442-723

Suwon

626-770

Yangsan

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT03205371 - Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers | Biotech Hunter | Biotech Hunter